J
Jiang Liu
Researcher at Fudan University
Publications - 59
Citations - 2788
Jiang Liu is an academic researcher from Fudan University. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 20, co-authored 54 publications receiving 1043 citations. Previous affiliations of Jiang Liu include Fudan University Shanghai Medical College.
Papers
More filters
Journal ArticleDOI
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
TL;DR: This review summarizes knowledge of the reciprocal interaction between antitumor immunity and distinct cell death mechanisms, particularly necroptosis, ferroPTosis, and pyroaptosis, which are the three potentially novel mechanisms of immunogenic cell death.
Journal ArticleDOI
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
Xiaoqi Mao,Jin Xu,Wei Wang,Chen Liang,Jie Hua,Jiang Liu,Bo Zhang,Qingcai Meng,Xianjun Yu,Si Shi +9 more
TL;DR: Cancer-associated fibroblasts (CAFs), a stromal cell population with cell-of-origin, phenotypic and functional heterogeneity, are the most essential components of the tumor microenvironment (TME). Through multiple pathways, activated CAFs can promote tumor growth, angiogenesis, invasion and metastasis, along with extracellular matrix remodeling and even chemoresistance.
Journal ArticleDOI
The microbiota and microbiome in pancreatic cancer: more influential than expected.
Miao Yan Wei,Si Shi,Chen Liang,Qing Cai Meng,Jie Hua,Yi Yin Zhang,Jiang Liu,Bo Zhang,Jin Xu,Xianjun Yu +9 more
TL;DR: A better understanding of the microbiota in PDAC might lead to the establishment of screening or early-stage diagnosis methods, implementation of cancer bacteriotherapy, adjustment of therapeutic efficacy even alleviating the adverse effects, creating new opportunities and fostering hope for desperate PDAC patients.
Journal ArticleDOI
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
Heng Zhu,Miaoyan Wei,Jin Xu,Jie Hua,Chen Liang,Qingcai Meng,Yiyin Zhang,Jiang Liu,Bo Zhang,Xianjun Yu,Si Shi +10 more
TL;DR: Deciding how to use PARP inhibitors in more clinical applications and how to avoid adverse effects, as well as prognosis and treatment response biomarkers, require additional research.
Journal ArticleDOI
Applications of single-cell sequencing in cancer research: progress and perspectives
TL;DR: The use of single-cell sequencing in cancer research has revolutionized our understanding of the biological characteristics and dynamics within cancer lesions, including information related to the landscapes of malignant cells and immune cells, tumor heterogeneity, circulating tumor cells and underlying mechanisms of tumor biological behaviors as mentioned in this paper.